Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot or scalpel? european trial tests less invasive pancreatic cancer surgery

NCT ID NCT04483726

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adults with resectable pancreatic cancer who are fit for either surgery type may join.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
minimally invasive distal pancreatectomy (laparoscopic or robot-assisted)
What this could lead to
If minimally invasive surgery proves as effective as open surgery, it could offer patients a less painful recovery with similar cancer outcomes.
What could go wrong
This is a relatively small early-phase trial, so results may not be definitive. Minimally invasive surgery may not remove the tumor as completely as open surgery in some cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Jul 2020

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years; * Elective indication for distal pancreatectomy for proven or suspected PDAC; * Upfront (without induction / down-sizing radio- and/or chemotherapy) resectable PDAC in the pancreatic body or tail; * The tumor can be radically resected via both minimally invasive or open surgery according to the local treating team; * The patient is fit to undergo both open and minimally invasive distal pancreatectomy Exclusion Criteria: * score of American society of anaesthesiologists (ASA) \>3; * A medical history of chronic pancreatitis (according to the M-ANNHEIM criteria); * Second malignancy necessitating resection during the same procedure; * Distant metastases (M1) including involved distant lymph nodes; * Tumor involvement or abutment of major vessels (celiac trunk\*, mesenteric artery or portomesenteric vein); * Pregnancy; * Participation in another study with interference of study outcomes. * Cystic lesion having undergone malignant transformation * the celiac trunk should be 5mm clear from tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • CHU Saint Eloi - Montpellier

    Montpellier, France

  • Centre Hospitalier Orléans

    Orléans, France

  • Hôpital Beaujon - APHP

    Clichy, France

  • Hôpital Paul Brousse

    Villejuif, France

  • Institut Mutualiste Montsouris

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.